Loading…

Chromoblastomycosis: a clinical and molecular study of 18 cases in Rio de Janeiro, Brazil

Background  Chromoblastomycosis (CBM) is a chronic subcutaneous mycosis caused by dematiaceous fungi. Methods  We described epidemiological data, clinical presentation, and treatment of 18 cases of CBM diagnosed in Rio de Janeiro, Brazil. Diagnosis was obtained by mycological, histopathological find...

Full description

Saved in:
Bibliographic Details
Published in:International journal of dermatology 2011-08, Vol.50 (8), p.981-986
Main Authors: Mouchalouat, Marcelle de F., Gutierrez Galhardo, Maria Clara, Zancopé-Oliveira, Rosely Maria, Monteiro Fialho, Paulo Cezar, de Oliveira Coelho, Janice Mery C., Silva Tavares, Patrícia Morais, Francesconi do Valle, Antonio Carlos
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background  Chromoblastomycosis (CBM) is a chronic subcutaneous mycosis caused by dematiaceous fungi. Methods  We described epidemiological data, clinical presentation, and treatment of 18 cases of CBM diagnosed in Rio de Janeiro, Brazil. Diagnosis was obtained by mycological, histopathological findings demonstrating typical muriform cells with confirmation of isolated by DNA sequencing of the ribosomal internal transcribed spacer. Results  The majority of patients were male (72.2%) ranging from 39 to 83 years old, farm laborers and construction workers. The duration of disease varied from four months to 32 years. The most common presentations were verrucous form in ten (55.6%) patients, followed by tumoral in three (16.7%) patients, primarily of moderate (55.6%) and severe (38.9%) intensity. Lower (44.4%) and upper limbs (33.3%) were the most affected sites. Fonsecaea pedrosoi isolated from 14 (77.8%), and Cladophialophora carrionii isolated from one case (5.6%). Fifteen patients (83.3%) were treated. Six patients (40%) received oral itraconazole 200–400 mg/day, five patients (33.3%) received oral itraconazole 200–400 mg/day combined with fluconazole 200 mg/day, and four (26.7%) patients were submitted to surgery. The duration of therapy varied from 12 to 48 months. Cure rate was 80% (12/15). No relapse was observed after two years of follow‐up. Conclusions  Success was due to attending a center with specialized clinical care, laboratory support, and pharmaceutical care.
ISSN:0011-9059
1365-4632
DOI:10.1111/j.1365-4632.2010.04729.x